Risk of osteonecrosis in systemic lupus erythematosus: An 11-year Chinese single-center cohort study

Lupus. 2021 Aug;30(9):1459-1468. doi: 10.1177/09612033211021166. Epub 2021 Jun 4.

Abstract

Objective: Osteonecrosis (ON), which can lead to physical disability, is a common complication of systemic lupus erythematosus (SLE). The purpose of this study was to determine the prevalence of ON and identify possible risk factors in Chinese SLE patients.

Methods: SLE patients who fulfilled the 1997 American College of Rheumatology SLE classification criteria were recruited from the Peking Union Medical College Hospital. The chi-square test (χ2 test) and multivariate regression analyses were used to evaluate risk factors. The Cox proportional-hazards model was used to construct the survival curves and estimate the simultaneous effects of prognostic factors on survival.

Results: We consecutively enrolled 1,158 patients, of which 88 patients (7.6%) developed ON. Among ON patients, 57.1% of patients had isolated femoral head necrosis and 42.9% had multiple joint involvement. The mean age of ON patients (24.62 ± 8.89 years) was significantly younger than SLE patients without ON (27.23 ± 10.16 years, p = 0.09). The ON group presented with a much longer disease course (10.68 ± 5.97 years, p < 0.001) and increased incidence of arthritis, kidney, and central nervous system (CNS) involvement (65.9% [p < 0.05], 57.6% [p < 0.05], and 16.5% [p < 0.05], respectively, in the ON group). ON patients were more likely to be treated with glucocorticoid (GC) and to receive a high dose of prednisolone at the initial stage of SLE (p < 0.05). The percentage of patients who received hydroxychloroquine was much higher in the control group (p < 0.001). Cox regression analysis suggested that CNS involvement and GC therapy were two independent risk factors for ON in SLE patients. The presence of anti-phospholipid antibodies (aPLs) was a risk factor for multiple joint necrosis (odds ratio: 6.28, p = 0.009).

Conclusions: ON remains a serious and irreversible complication in SLE. In addition to glucocorticoid therapy, we found that CNS system involvement was a risk factor for ON, while the administration of hydroxychloroquine was a protective factor. The clinical characteristics of multiple site ON patients were distinct from isolated femoral head necrosis patients. The presence of aPLs was a risk factor for multiple site osteonecrosis.

Keywords: Systemic lupus erythematosus; anti-phospholipid antibodies; osteonecrosis; risk factors.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Antiphospholipid / blood
  • Antirheumatic Agents / therapeutic use
  • China / epidemiology
  • Cohort Studies
  • Female
  • Femur Head Necrosis / blood
  • Femur Head Necrosis / epidemiology
  • Femur Head Necrosis / etiology
  • Glucocorticoids / adverse effects
  • Glucocorticoids / therapeutic use
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Lupus Erythematosus, Systemic* / blood
  • Lupus Erythematosus, Systemic* / complications
  • Lupus Erythematosus, Systemic* / drug therapy
  • Lupus Erythematosus, Systemic* / epidemiology
  • Male
  • Osteonecrosis* / blood
  • Osteonecrosis* / epidemiology
  • Osteonecrosis* / etiology
  • Prednisolone / adverse effects
  • Prednisolone / therapeutic use
  • Prevalence
  • Risk Factors
  • Young Adult

Substances

  • Antibodies, Antiphospholipid
  • Antirheumatic Agents
  • Glucocorticoids
  • Hydroxychloroquine
  • Prednisolone